Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2007

View Archived Issues

Almirall acquires Hermal skincare business from Reckitt Benckiser

Profectus receives grant to develop anti-HIV antibodies

Taxus Element Stent begins new program

New antiinfective drugs disclosed in recent patent literature

New treatment options for neurological diseases claimed in recent patents

EpiCept NP-1 enters phase IIb and phase III studies for multiple indications

Schering-Plough announces acadesine licensing for cardiac surgery complications

Forbes Medi-Tech on track for corporate objectives and revenue growth

GW Pharmaceuticals's E.U. regulatory withdrawal

Meda enters U.S. market through strategic acquisition of MedPointe

Elan and Biogen Idec will appeal ruling on European application for natalizumab

FDA allows IND for Cougar Biotechnology's noscapine

Results from Samaritan's phase IIb study of novel HIV entry inhibitor

Tercica completes clinical trial enrollment for Increlex in pediatric primary IGFD

Phase I study to examine the safety and anticancer efficacy of the novel TCR/IL-2 fusion protein

Sygnis' phase IIa study of AX-200 for stroke completed

Ark withdraws EMEA early marketing approval application of Cerepro

FDA accepts QLT's labeling sNDA for Aczone

FDA grants permission to Kinex to proceed to phase I trials of KX2-391

Novel HCV NS5B polymerase inhibitors emerge from Pfizer R&D

Advisory committee recommendation for Evista in breast cancer risk reduction

Preliminary clinical safety of the recombinant gag-env HIV-1 protein-based vaccine VICHREPOL shown

Wyeth receives approvable letter for Pristiq in menopause-related vasomotor symptoms

CCR5 antagonist INCB-009471 exerts potent, prolonged antiretroviral activity in HIV patients

PF-429242: Example of novel S1P inhibitors for dyslipidemia and related disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...